Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Revenue growth
Gilead Sciences, Inc.'s revenue growth over the twelve months to 30 June 2026 was 5.52%, up 3.1 percentage points from fiscal 2025 (2.40%). Over the past ten years it has ranged from −15.2% (fiscal 2018) to 31.1% (fiscal 2015); the current reading is higher than 64% of that period. That is below the Drug Manufacturers General industry median of 6.79% and below the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 2.40% | (3.64) |
| FY2024 | 6.04% | 6.64 |
| FY2023 | −0.60% | (0.51) |
| FY2022 | −0.09% | (10.69) |
| FY2021 | 10.6% | 0.62 |
| FY2020 | 9.98% | 8.52 |
| FY2019 | 1.46% | 16.70 |
| FY2018 | −15.2% | (1.15) |
| FY2017 | −14.1% | (7.20) |
| FY2016 | −6.89% | (38.02) |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 10.2% | 5.79 |
| Mar 2026 | 4.39% | (0.31) |
| Dec 2025 | 4.70% | 1.73 |
| Sep 2025 | 2.97% | 1.13 |
| 42 more quarters | Free account |
Against its own ten years
Low −15.2%
High 31.1%
Ten-year median
1.46%
Current reading's percentile
64
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 21.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 9.10% |
| GSK GSK PLC Sponsored ADR compare | 8.72% |
| AZN AstraZeneca PLC compare | 8.61% |
| GILD Gilead Sciences, Inc. | 5.52% |
| BMY Bristol Myers Squibb Company compare | 3.11% |
| NVS Novartis AG compare | 2.73% |
| PFE Pfizer Inc. compare | −0.21% |
| Drug Manufacturers General industry median | 6.79% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement